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Abstract
Angiogenesis plays a key role in tumor growth and cancer progression. TIE-2-expressing
monocytes (TEM) have been reported to critically account for tumor vascularization and
growth in mouse tumor experimental models, but the molecular basis of their pro-angiogen-
ic activity are largely unknown. Moreover, differences in the pro-angiogenic activity between
blood circulating and tumor infiltrated TEM in human patients has not been established to
date, hindering the identification of specific targets for therapeutic intervention. In this work,
we investigated these differences and the phenotypic reversal of breast tumor pro-angio-
genic TEM to a weak pro-angiogenic phenotype by combining Boolean modelling and ex-
perimental approaches. Firstly, we show that in breast cancer patients the pro-angiogenic
activity of TEM increased drastically from blood to tumor, suggesting that the tumor micro-
environment shapes the highly pro-angiogenic phenotype of TEM. Secondly, we predicted
in silico all minimal perturbations transitioning the highly pro-angiogenic phenotype of tumor
TEM to the weak pro-angiogenic phenotype of blood TEM and vice versa. In silico predicted
perturbations were validated experimentally using patient TEM. In addition, gene expres-
sion profiling of TEM transitioned to a weak pro-angiogenic phenotype confirmed that TEM
are plastic cells and can be reverted to immunological potent monocytes. Finally, the re-
lapse-free survival analysis showed a statistically significant difference between patients
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with tumors with high and low expression values for genes encoding transitioning proteins
detected in silico and validated on patient TEM. In conclusion, the inferred TEM regulatory
network accurately captured experimental TEM behavior and highlighted crosstalk between
specific angiogenic and inflammatory signaling pathways of outstanding importance to con-
trol their pro-angiogenic activity. Results showed the successful in vitro reversion of such an
activity by perturbation of in silico predicted target genes in tumor derived TEM, and indicat-
ed that targeting tumor TEM plasticity may constitute a novel valid therapeutic strategy in
breast cancer.
Author Summary
Tumor vascularization is essential for tumor growth and cancer progression. In breast can-
cer, monocytes are angiogenic, i.e. able to induce tumor vascularization. In patients, blood
circulating monocytes drastically increase their angiogenic activity when reaching the
tumor, suggesting that the tumor microenvironment shapes their angiogenic activity. The
identification of the tumor signals inducing the angiogenic activity of monocyte is of para-
mount significance because it represents the rationale for anti-angiogenic therapies in
breast cancer. This goal was achieved by constructing an integrative model of monocyte
behavior based on experimental data. The model predicted treatments abrogating the an-
giogenic activity of monocytes, which were experimentally validated in monocytes isolated
from patient breast carcinoma. Importantly, these treatments reverted angiogenic mono-
cytes into immunological potent cells. The main outcome of this modeling strategy for ex-
perimental and clinical oncology is the identification of effective treatments abrogating the
angiogenic activity of monocytes and thus simultaneously revealing their
functional plasticity.
Introduction
Elucidating the various cell signaling cascades, pathway crosstalk, and how they influence final
cell fate and behavior is crucial for defining therapeutic intervention points aimed at driving a
cell towards a desired state. To this end, modeling approaches can be used to perturb a biologi-
cal system in silico to test hypotheses on a scale that would be unfeasible to test experimentally.
Boolean models have been extensively used in the past to simulate the behavior of cells based
on their network activity [1]. In a Boolean modeling approach, the nodes in a regulatory net-
work represent the state of activation of a gene (protein, receptor or ligand) using discrete vari-
ables (On or Off). The state of the network at a given instant can change depending on the
state of the other nodes and can ultimately stabilize into attractors of either a single state
(steady state) or an oscillating set of states (cycling attractors) [2]. Introducing perturbations in
a biological regulatory network can change the attractors and even transition the system from
one attractor to another one. The Boolean steady state of the network has been shown to corre-
spond to the cellular states for various regulatory networks in the past [3]. Boolean modeling of
steady state transitions helps in understanding the influence of perturbations on system wide
behavior and has been used to identify the key molecular mechanisms controlling gene expres-
sion [4,5,6] and regulation [7,8], cell differentiation [9] and signal transduction
[10,11,12,13,14,15,16,17,18,19,20]. Most of these models were developed in synergy by wet and
dry laboratories. However, to date, only few of them have reported experimental validations (in
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primary cells) of the proposed in silico predictions [12,15,16]. In the present study we describe
the application of a Boolean modeling based approach to investigate the molecular mecha-
nisms underlying the angiogenic function of tumor monocytes from breast cancer patients and
the experimental validation of in silico predictions derived from this modeling.
The formation of tumor-associated vasculature, a process also referred to as tumor angio-
genesis, is essential for tumor progression. Tumor vessels can form from local pre-existing
capillaries. This process is promoted by the recruitment of bone marrow-derived angiogenic
cells (i.e. mainly monocytes, dendritic cells and neutrophils) at tumor sites [21,22,23]. Clinical
studies have demonstrated in a variety of human solid tumors a positive correlation between
increased micro-vessel density, infiltration of tumor-associated macrophages (TAM) [24] and
unfavorable prognosis in cancer patients [25,26,27,28,29,30,31,32,33]. Recently, monocytes ex-
pressing the TIE-2/tek receptor tyrosine kinase (TEM: TIE-2 expressing monocytes) have been
identified in peripheral blood and tumors of humans and mouse [34,35]. In experimental
mouse models, TEM recruited to tumors accounted for apparently all angiogenic activity of
bone marrow-derived cells since their selective ablation fully suppressed angiogenesis and in-
duced tumor regression [34]. Hence, TEM appear to be key players in tumor angiogenesis but
the tumor micro-environmental signals and the related signaling pathways governing their
functions remain to be elucidated. Of particular interest from a disease standpoint is how TEM
can be directed away from potentiating tumor angiogenesis and progression to monocytes
being immunologically potent cells.
The VEGFR-1 (Vascular Endothelial Growth Factor Receptor-1), TGFBR-1 (Tumor
Growth Factor β Receptor-1), TNF-R1 (Tumor Necrosis Factor Receptor-1) pathways have
been reported to regulate tumor angiogenesis [36,37], but their activities have not been exam-
ined in human TEM. While we have previously reported that TIE-2 and VEGFR kinase
Table 1. Clinical and pathological features of tumors and patients (n = 40).
Patient characteristics %
Age, years
<50 29.6
50 70.4
Surgical treatment
Mastectomy 32.1
Tumorectomy 67.9
Lymph node status
Negative 74.5
Positive 25.5
Tumor
T1 57.1
T2< 3cm 42.9
Histology
Ductal 84.7
Lobular 11.5
Others 3.8
Grade
I 30.8
II 38.4
III 30.8
doi:10.1371/journal.pcbi.1004050.t001
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activities drive immunosuppressive function of TEM in human breast Cancer [38], in this
study, we investigated the contribution of these pathways along with TGFBR-1 and TNF-R1
pathways to TEM pro-angiogenic activity. We observed that the pro-angiogenic activity of
TEM increased drastically from blood to tumor in breast cancer patients. We constructed an
integrative and predictive model of TEM behavior to predict in silico all minimal perturbations
that can transition the highly pro-angiogenic phenotype of breast tumor TEM into a weak pro-
angiogenic phenotype and vice versa. By experimentally validating our computational predic-
tions, we demonstrate here that the inferred regulatory network captured accurately patient
TEM behavior. Thus, the contribution of the computational approach was not only essential to
predict and tune TEM pro-angiogenic activity but also to identify the key underlying compo-
nents and pathways of their pro-angiogenic activity. Finally, gene expression profiling of TEM
transitioned to a weak pro-angiogenic phenotype confirmed that TEM infiltrating carcinoma
of the breast remain plastic cells that can be reverted from pro-angiogenic and protumoral cells
to immunological potent monocytes.
Results
TEM from peripheral blood and tumor tissue of breast cancer patients
show distinct pro-angiogenic phenotypes
The angigoenic profile of TEM was investigated in a group of 40 newly diagnosed breast
cancer patients (Table 1). We characterized by flow cytometry the phenotype of TEM from
patient peripheral blood and freshly dissociated tumor specimens obtained at time of surgery
(see Material and Methods). Based on our immunostaining and flow cytometry protocol we
observed that TEM did not constitute a distinct subset of monocytes. In contrast, all monocytes
showed expression of TIE-2, which was particularly low in patient blood and substantially
higher on monocytes isolated from tumor tissue (S1 Fig. and Table 2). Thus, CD11b+, CD14+
monocytes from patient blood and tumor tissue were referred to as “TEM” and compared with
respect to receptor and cytokine expression. However, tumor TEM co-expressed VEGFR-1
and TGFR-1 at significantly higher levels compared to peripheral blood TEM (Table 2). We
next assess the pro-angiogenic activity of TEM using the in vivo corneal vascularization assay
[39]. The cornea itself is avascular and was injected with TEM isolated from patient peripheral
blood and tumor tissue. Thus, any growth of new vessels from the peripheral limbal vasculature
must be due to injected TEM and reflect their pro-angiogenic activity. Tumor TEM showed a
heterogeneous and consistently high pro-angiogenic activity inducing cornea and iris
Table 2. Expression levels of receptors and integrin measured by ﬂow cytometry at the surface of
TEM.
Tumor TEM Blood TEM ivdTEM
TIE-2 4.09+/- 2.5 1.63+/- 0.71 2.56+/- 0.78
VEGFR-1 6.5+/- 3.24 1.09+/- 0.47 2.42 +/- 1.40
TGFBR-1 113.05+/- 29.1 2.08+/- 0.66 3.50+/- 1.13
TNF-R1 1.39+/- 0.61 1.50+/- 0.76 1.69+/- 0.41
CCR5 1.03+/- 0.20 0.81+/- 0.17 1.03+/- 0.10
α5β1 1.94+/- 1.30 1.27+/- 0.18 nd
CXCR4 1.37+/- 0.4 2.18+/- 2.08 nd
Mean fold increase to isotype control antibodies +/- standard deviation (n = 10) is indicated. Signiﬁcant
differences (P<0.05) are in bold, nd not determined
doi:10.1371/journal.pcbi.1004050.t002
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vascularization. By contrast, blood TEM were unable to induce de novo vascularization of the
cornea but did increase the pre-existing vascular network of the iris (Fig. 1A). Thus, tumor and
blood TEM show distinct pro-angiogenic phenotypes with the expression levels of TIE-2,
VEGFR-1 and TGFR-1 mirroring their pro-angiogenic activity (Fig. 1A and Table 2). Finally,
secretions were profiled in the conditioned medium of patient-isolated TEM and revealed that
Fig 1. Phenotypical signature of pro-angiogenic TEM. (A) In vivo corneal vascularization assay to assess the pro-angiogenic activity of TEM isolated from
peripheral blood and tumor of breast cancer patients. Bright field pictures of the eyes and fluorescent microscopy images of sagittal sections of the eyes
stained with CD31 (stains specifically blood vessel endothelial cells) and Dapi (stains cell nucleus) are shown. Double-head and single arrows depict cornea
and iris respectively. Corneas of control eyes were injected with buffer alone and show similar vascularization to uninjected eyes. Note the presence of blood
vessels in the cornea injected with tumor TEM (double-head arrow) and its absence in the corneas injected with buffer (control) or blood TEM. Shown are
representative data of 10 experiments. Bars in bright field and fluorescent images are 500 and 100 μm respectively. Bar graph represents a quantification of
the vascular network of the cornea and the iris. (B) Secretion profile of cytokines and angiogenic factors in TEM isolated from patient blood and tumor.
Angiogenic factors are boxed. Shown are cumulated data of 5 experiments, significant variations (P< 0.05) are indicated with an asterisk. (C) Workflow
diagram of the strategy combining experimental and computational approaches to discover anti-angiogenic therapies. Green: experiments using ivdTEM.
Blue, experiments using patient TEM; red: computational approach.
doi:10.1371/journal.pcbi.1004050.g001
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tumor TEM are paracrine inducers of tumor angiogenesis by releasing high levels of angiogenic
factors (i.e. VEGF, bFGF, and ANG-1) and MMP9 (matrix metalloproteinase 9) (Fig. 1B).
Blood and tumor TEM display a mixed M1-like (tumor-associated macrophages releasing in-
flammatory molecules) and M2-like (immunosuppressive macrophages polarized by anti-in-
flammatory molecules) phenotype, with secretion of both the pro- and anti-inflammatory
cytokines IL-12 and IL-10, respectively (Fig. 1B). Given that TEM circulating in the blood infil-
trate tumor tissue where they further differentiate [34], our data suggest that the tumor micro-
environment shapes their highly pro-angiogenic phenotype.
Combining computational and experimental approaches to delineate the
pathways controlling TEM pro-angiogenic function
The identification of the ligands and the pathways controlling the highly pro-angiogenic activi-
ty of tumor TEM is of paramount significance because it represents the rationale for a treat-
ment directing TEM away from being cells supporting tumor growth. The strategy we selected
to reach this goal combined computational and experimental approaches to simulate and pre-
dict the behavior of patient TEM subjected to various ligand combinations. Given the limited
amounts of patient specimens and the low frequency of TEM (TEM represented 6.7% ±2.5% of
peripheral blood mononuclear cells and 22% ±2.7% of the tumor hematopoietic infiltrate),
only a limited number of ligand combinations could be investigated experimentally. The avail-
ability of limited amounts of patient TEM was partially overcome by taking advantage of our
recently developed model system of TEM differentiated in vitro by exposing CD34+ cord blood
hematopoietic progenitors to breast cancer cell conditioned culture medium [38,40]. In vitro
differentiated TEM (thereafter named ivdTEM) are angiogenic [38,40] and display an interme-
diate phenotype relative to blood and tumor TEM (Table 2). Consistent with their phenotype
(Table 2), ivdTEM released intermediate amounts of angiogenic factors relative to blood and
tumor TEM (Table 3).
Moreover, the in silicomodeling and predictions helped us to focus on the most clinically
relevant monocytic ligands and to spare precious patient specimen. The workflow of our ap-
proach consists of five steps (Fig. 1C): 1) experimental measurement of the responses of TEM
differentiated in vitro to a set of ligands, 2) construction of a dynamic regulatory network
based on these experimental data, 3) in silico prediction of the treatments altering TEM behav-
ior, 4) experimental validation of computationally predicted treatments using ivdTEM and 5)
validation the best predicted treatments in patient TEM (Fig. 1C). Finally, to help shed light on
possible molecular mechanisms underlying TEM pro-angiogenic transformation, we selected
several treatment combinations and measured genome wide expression profiles for the TEM
differentiated in vitro, comparing the state of the cells before and after treatment.
Table 3. TEM release of angiogenic factors measured by ﬂow cytometry.
Tumor TEM Blood TEM ivdTEM
MMP9 32.1+/- 5.7 9.36+/- 2.2 14+/- 3.1
VEGF 5.2+/- 2.1 0.21+/- 0.1 1.57 +/- 0.6
ANG-1 28.1+/- 7.5 1.2+/- 0.7 7.8+/- 1.3
Mean secretions +/- standard deviation (n = 5) in pg/ml and 104 cells are indicated. Signiﬁcant differences
(P<0.05) are in bold.
doi:10.1371/journal.pcbi.1004050.t003
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Identification of critical ligands impacting the phenotype and pro-
angiogenic activity of TEM differentiated in vitro—Antagonistic effect of
TGF-β and synergistic effects of TNF-α on TEM pro-angiogenic
phenotype and function
Our strategy was to expose TEM to several treatments to identify the ligands and pathways crit-
ically controlling their pro-angiogenic activity. TEM differentiated in vitro were exposed to an-
giogenic factors (VEGF, PlGF and ANG-1, ANG-2 which are the ligands of VEGFR-1 and
TIE-2 respectively) in combination with either TGF-β or TNF-α and the changes in their phe-
notype, angiogenic activity and paracrine secretion profile were examined. These experimental
results were used as the foundations for a computational model that would allow predicting
treatments increasing or dampening TEM proangiogenic activity. First, changes in TEM phe-
notype were evaluated by flow cytometry 36h post treatment. Globally, treatments combined
with TGF-β or TNF-α displayed a stronger impact on TEM phenotype than single treatments
with however, the exception of TGF-β. Overall, CD11b, CD14, VEGFR-1 and TIE-2 expression
displayed larger changes in response to treatment than CCR5, TNF-R1 and TGFBR-1
(Fig. 2A). A hallmark of TGF-β treatments was a strong decrease in VEGFR-1 and CD11b ex-
pression and an increase in TIE-2 expression (Fig. 2A). By contrast, TNF-α treatments had no
impact on VEGFR-1 expression and TNF-α increased TIE-2 expression when combined with
PlGF or ANG-2 (Fig. 2A).
We assessed the impact of the treatments on the pro-angiogenic activity of TEM using in
vitroHUVEC (Human Umbilical Vascular Endothelial Cells) sprouting assay (see Methods).
Treated TEM were applied to HUVEC grown on microcarrier beads and embedded in a fibrin
gel to measure their aptitude to induce HUVEC sprouting i.e. the initial step of blood vessel
formation. Single treatments show no significant impact on TEM proangiogenic activity rela-
tive to untreated cells with the exception of TGF-β which significantly reduced TEM pro-an-
giogenic activity (Fig. 2B). Interestingly, combining TGF-β with PlGF further decreased
VEGFR-1 expression (Fig. 2A) and TEM proangiogenic activity (Fig. 2B) suggesting that TGF-
β synergized with PlGF to reduce TEM proangiogenic activity. We examined the impact of
combined treatments on TEM using in vivo corneal vascularization assay. Indeed, in vitro
sprouting assay was preferred for quantification but is however less reliable because it does not
recapitulate the intricate balance of signals from growth factors, mural cells and extracellular
matrix of in vivo angiogenesis. TNF-α in combination with ANG-2 (or PlGF) significantly in-
creased TIE-2 expression whilst leaving VEGFR-1 expression unchanged (Fig. 2A), and raised
TEM pro-angiogenic activity (Fig. 2C. Cornea and iris vascularization in AU: control: 1; un-
treated: 1.81; TNF-α+Ang-2: 4.58). Conversely, TGF-β in combination with VEGF resulted in
a comparable induction of TIE-2 but decreased VEGFR-1 expression (Fig. 2A), and reduced
TEM pro-angiogenic activity (Fig. 2C. Cornea and iris vascularization in AU: TGF-β+VEGF:
1.36). Taken together these results show, for the first time, that both Tie2 and VEGFR1 path-
ways control TEM pro-angiogenic activity. Furthermore, TIE-2 and VEGFR1 pathways syner-
gized with the TNF and TGF pathway to induce and reduce TEM pro-angiogenic
activity respectively.
Finally, we examined the impact of the different ligand treatments on TEM secretions.
Thus, cumulated TEM secretions from ivdTEM were measured experimentally and the secre-
tions for TEM were mathematically inferred (ivdTEM correspond to double positive DP cell
population, see Materials and Methods and S2 Fig.) and display in Fig. 2D. Of note, none of the
single or double treatments we have examined experimentally (Fig. 2D) shifted completely the
paracrine secretion profile of TEM differentiated in vitro toward that of blood or tumor TEM
(compare Fig. 2D and 1B). These results suggest that transitioning ivdTEM into blood or
Angiogenic Activity of Breast Cancer Patients' Monocytes Reverted
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tumor TEM requires a model to simulate computationally the impact of a larger number of li-
gand combinations on TEM behavior.
Construction of dynamical models from the experimental data using
TEM differentiated in vitro
The limited amounts of patient TEM and the combinatorial nature of the ligands precluded ex-
perimental testing of all the ligand combinations and was the rationale for building an integra-
tive and predictive model of TEM behavior. We used TEM differentiated in vitro to derive a
dynamical regulatory network from experimental data obtained with a selected number of li-
gands (Fig. 2) and used then as a proxy to assess the clinically most relevant ligand combina-
tions. To create the models, data sets of receptor expression (Fig. 2 and S2 Table) and paracrine
Fig 2. Synergistic and antagonistic effects of TNF-α, PlGF, ANG-2 and TGF-β on TEM pro-angiogenic phenotype. IvdTEMwere exposed to different
combinations of ligands and changes in the expression of receptors at their surface of wasmeasured by flow cytometry 36 hours post-treatment and displayed
asmean log2 ratios relative to untreated cells (A). Significant variations (P< 0.05, T test) in VEGFR-1 and TIE-2 expression in TEM are indicated with an
asterisk in the heatmap. Changes in TEM pro-angiogenic activity in response to treatments was measures in vitro (B) and in vivo (C) using HUVEC sprouting
assay and corneal vascularization assay respectively, 3 to 5 independent angiogenic assays were performed per condition. * P< 0.05, ** P< 0.01. (D) The
secretion of cytokines and angiogenic factors in response to treatments was experimentally measured in the conditioned medium of the culture 36 hours post-
treatments. The secretions of ivdTEMweremathematically inferred and displayed asmean log2 ratios relative to untreated cells. Angiogenic factors are boxed.
Shown are cumulated data of 3 to 10 independent experiments (panels A and D), the corresponding experimental data and all P values are available in S2 and
S3 Tables.
doi:10.1371/journal.pcbi.1004050.g002
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secretion profiles (Fig. 2 and S3 Table) were combined to infer relevant relationships (or links)
between ligands and receptors. Briefly, relevant links were identified based on the amplitude of
their expression or secretion changes, their reproducibility, and their coherent variations across
the treatments (see Methods). Based on these criteria, amongst 924 possible links (7 receptors ×
11 secreted factors × 12 treatments) we retained 74 relevant links (S4 Table). Globally, TNF-α,
TGF-β and PlGF appeared as key regulators of TEM network. However, TNF-α in contrast to
TGF-β, was strongly regulated by other factors (Fig. 3). Dynamical Boolean modeling was then
performed by integrating the retained links into an algorithm for computing Minimal Interven-
tion Set (MIS) of TEM regulatory network. Given a regulatory network, MIS patterns represent
a set of simultaneous perturbations (or treatments) to force the network into a desired steady
state, where a subset of nodes remain at a fixed expression level of either low or high [41,42].
The term minimal implies that no other sub-set of an MIS pattern can lead to the desired steady
state behavior. However, for a given network, there can be more than one MIS patterns to gener-
ate the same steady state. The MIS algorithm proposed by Garg et al [43,44] was used for assess-
ing TEM regulatory network by computationally predicting all possible set of up to three
simultaneous treatments that can force the TEM network into a weakly (i.e. blood TEM) or
highly (i.e. tumor TEM) pro-angiogenic phenotype.
The plasticity of TEM predicted computationally was validated
experimentally using TEM differentiated in vitro
Relative to their blood counterparts, tumor TEM display a higher pro-angiogenic activity
(Fig. 1A), a paracrine profile shifted toward angiogenesis (Fig. 1B) and higher levels ofTIE-2
and VEGFR-1 (Table 2). Therefore blood and tumor TEM can be viewed as two distinct cell
steady state behaviors and ivdTEM as an intermediate state (Tables 2 and 3). Using the regula-
tory network model of TEM differentiated in vitro we predicted the minimal treatments re-
quired for transitioning tumor TEM to blood TEM and vice versa. Because the expression
levels of TIE-2 and VEGFR-1 controlled (Fig. 2) and mirrored (Fig. 1B) TEM pro-angiogenic
activity, we assigned to TIE-2 and VEGFR-1 nodes a fixed polarity of either both over-express-
ed or down-modulated for highly pro-angiogenic (i.e. tumor TEM) or weakly pro-angiogenic
(i.e. blood TEM) steady states respectively. Computationally predicted minimal perturbations
sets (MIS) are reported in Table 4. It is interesting to note that all the predicted treatments
were composed of at least two, and mostly three simultaneous perturbations. Only one treat-
ment, combining three perturbations, was predicted by the model to promote TEM pro-angio-
genic activity (TNF-α, ANG-2 and PlGF; Table 4). Conversely, eleven distinct treatments were
predicted to dampen TEM proangiogenic activity and resulted in three main groups (Table 4).
The first group of treatments combined TIE-2 tyrosine kinase inhibitor with TGF-β and a li-
gand of VEGFR-1 or TIE-2. Treatments from the second group involved VEGFR-1 kinase in-
hibitor, and the third group of treatments associated TGF-β with TNF-α and a ligand of TIE-2
or VEGFR-1 (Table 4). It is worth noting here that we assumed that possible compensatory
mechanisms resulting from the blocking of the receptor signaling (rather than knocking down
the receptor) do not significantly affect the angiogenic activity. Results showed that this as-
sumption was valid for the particular case of the receptors under study.
With currently available tools, VEGFR-1 kinase activity is almost impossible to manipulate.
Indeed, to date, all available VEGFR-1 kinase inhibitors also inhibit VEGFR2 and VEGFR3
to a lesser extent, thus preventing experimental validation of any treatment of the second
group. For experimental validations, we therefore selected the combined TNF-α/ANG-2/PlGF
treatment, predicted to promote angiogenesis, two treatments of the first group (TIE-2inhibi-
tor/TGF-β/PlGF, and TIE-2 inhibitor/TGF-β/ANG-2), one treatment of the third group
Angiogenic Activity of Breast Cancer Patients' Monocytes Reverted
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(PlGF/TGF-β/TNF-α) and a TIE-2 kinase inhibitor alone. These experimental validations were
first conducted in TEM differentiated in vitro.
As predicted, the TNF-α/ANG-2/PlGF combined treatment induced TIE-2 and VEGFR-1
expression (Fig. 4A) and increased their proangiogenic activity (Fig. 4B). Importantly, this
combined treatment induced TIE-2 and VEGFR-1 expression and TEM pro-angiogenic activi-
ty more efficiently than PlGF/TNF-α (Fig. 4A) and PlGF or ANG-2 single treatments
Fig 3. ivdTEM network topology.Dynamical models of treatments/receptors/cytokines interactions in ivdTEM. Inputs (treatments) and output (receptor and
secreted soluble factors) are depicted in yellow and red respectively. Factors that were used as treatment and measured as output are depicted in orange.
Combined treatments (network nodes i.e. AND) are represented as small pink circles. Stimulatory and inhibitory effects of single or combined treatments are
depicted by black arrow-headed edges and green edges respectively. Circles and diamonds represent soluble factors and receptors respectively. All the
links presented are provided in S4 Table. Boolean equations used for representing ivdTEM regulatory networks are provided in S6 Table.
doi:10.1371/journal.pcbi.1004050.g003
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(Fig. 2A and B). These results validate our in silico prediction and reveal the synergistic effect
of TIE-2, VEGFR-1 and TNF-α pathways in controlling TEM pro-angiogenic activity.
The predicted inhibitory effect of the other treatments was assessed on TEM pre-treated
withTNF-α/ANG-2/PlGF, which display an increased pro-angiogenic phenotype compared to
untreated cells (Fig. 4A and B). This pre-treatment increased the dynamic range and therefore
the sensitivity of detecting inhibitory effects. TIE-2 kinase inhibitor/TGF-β combined with
ANG-2 or PlGF significantly decreased TIE-2 and VEGFR-1 receptor expression (Fig. 4A) con-
sistently reduced their pro-angiogenic activity (Fig. 4B). The PlGF/TGF-β/TNF-α treatment
was not as effective, but still reduced their pro-angiogenic activity. These combined treatments
were synergistic and minimal since TIE-2 kinase inhibitor (Fig. 4A and B) or single treatments
alone (Fig. 2A and 2B) or double treatments (PLGF/TGF-β or TIE-2inhibitor/TGF-β display
on Fig. 2B and Fig. 4B, respectively) were not sufficient to decrease VEGFR-1 expression and
TEM pro-angiogenic activity. By contrast, PlGF/TGF-β/TNF-α heterogeneously decreased
TIE-2 and VEGFR-1 expression (Fig. 4A) and TEM pro-angiogenic activity (Fig. 4B). In sum-
mary, from these validation experiments we found that the best computationally predicted
treatment promoting TEM pro-angiogenic activity was TNF-α/ANG-2/PlGF and the best
dampening activity was found using TIE-2 kinase inhibitor/TGF-β associated with a ligand of
TIE-2 or VEGFR-1.
Table 4. Computationally predicted minimal perturbations sets (MIS) required for transitioning TEM regulatory network into highly or weakly
pro-angiogenic TEM.
RTK activity
inhibited
Up-regulated Inﬂammatory
Ligand
Up-regulated VEGFR-1
ligand
Up-regulated TIE-2
ligand
Transition to weakly pro-
angiogenic TEM
Group
1
TIE-2 TGF-β VEGF -
TIE-2 TGF-β PlGF -
TIE-2 TGF-β - ANG-1
TIE-2 TGF-β - ANG-2
Group
2
VEGFR-1 TNF-α - ANG-1
VEGFR-1 TNF-α VEGF -
VEGFR-1 - all but PlGF -
TIE-2 and VEGFR-
1
- - -
Group
3
- TNF-α and TGF-β PlGF -
- TNF-α and TGF-β - ANG-1
- TNF-α and TGF-β VEGF -
Transition to highly pro-
angiogenic TEM
- TNF-α PlGF ANG-2
These two ﬁnal desired cell steady states were obtained by assigning to TIE-2 and VEGFR-1 nodes a ﬁxed polarity of either both high (highly pro-
angiogenic i.e tumor TEM) or low (weakly proangiogenic i.e. blood TEM) expression levels. Computationally predicted MIS decreasing TEM pro-
angiogenic activity were classiﬁed in three groups based on the receptor tyrosine kinase (RTK) inhibited and inﬂammatory (TGF-β or TNF-α) and
angiogenic ligands up-regulated.
doi:10.1371/journal.pcbi.1004050.t004
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ANG-2/ TGF-β and PlGF/ TGF-β treatments increased transcript
abundance of genes regulating differentiation and immune response of
TEM differentiated in vitro
Having identified the critical ligands and pathways controlling TEM plasticity, we next exam-
ined in TEM differentiated in vitro whether differential gene expression might also contribute
to the molecular basis of TEM plastic behavior. This analysis may shed light on the molecular
Fig 4. Experimental validation of in silico predicted treatments using ivdTEM. TEM differentiated in vitro were exposed to the treatments predicted in
silico and their changes in TIE-2 and VEGFR-1 expression (A) and pro-angiogenic activity (B) measured by flow cytometry and in vitro angiogenesis
sprouting assay respectively. The impact of inhibitory treatments was examined on ivdTEM previously treated with TNF-α/PlGF/ANG-2 (panels A and B).
Significant variations (P< 0.05) are indicated with an asterisk. In panel A, small and large asterisks referred to VEGFR-1 and TIE-2 expression respectively.
doi:10.1371/journal.pcbi.1004050.g004
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mechanisms underlying the observed TEM responses. To this end, we selected VEGF/TNF-α,
ANG-2/TGF-β and PlGF/TGF-β treatments for gene expression profiling using Affimetrix
whole genome microarrays, because these treatments were present in 17, 16 and 14, respective-
ly of the 74 links (treatment/receptor/cytokine) retained in TEM regulatory network (S4 Table
and Fig. 3). All the other treatments occurred less frequently. Hierarchical clustering demon-
strated that TGF-β-based treatments (ANG-2/TGF-β and PlGF/TGF-β) clustered separately
from VEGF/TNF-α and control treatments. A total of 398 genes were significantly (p<0.05)
and differentially expressed between the two clusters among which 369 and 72 genes were al-
tered by TGF-β/ANG-2 and TGF-β/PlGF treatments respectively (S5 Table, NT unique lists)
while 43 were regulated in common (S5 Table, NT intersect list). Enrichment analyses of the
gene expression data against known pathways and functional gene categories were conducted
as described in Materials and Methods. No enrichment of specific pathways of interest was
observed due to the fact that the gene annotations were too general and did not correspond to
specific functions of monocytes. Therefore, the 398 differentially expressed genes were annotat-
ed and classified in categories manually (S5 Table). Similar expression profiles were obtained
for untreated and TNF-α/VEGF treated cells consistent with their weak impact on TEM func-
tional angiogenic phenotype (Fig. 2). By contrast, ANG-2/TGF-β and PlGF/TGF-β treatments
inhibited TEM pro-angiogenic activity (Fig. 2) and down-modulated the expression of pro-an-
giogenic genes (Fig. 5 and S5 Table). Furthermore and interestingly, the expression of VASH1
(vasohibin 1) and UCN (urocortin) genes coding for anti-angiogenic proteins was simultaneous-
ly up-regulated (Fig. 5 and S5 Table). In response to both ANG-2/TGF-β and PlGF/TGF-β
treatments, 95% of the genes functionally related to the cell cycle displayed a down-modulated
expression indicating that TEM stopped proliferating with profound changes in their metabo-
lism but without, however undergoing apoptosis (the expression of metabolism and apoptosis
related genes was down-modulated for 76% and 88% of them respectively). TEM treated with
TGF-β/ANG-2 or TGF-β/PlGF show the expression of some genes (P2RY12, TMCC3, NPDC1,
IFFO1, UBASH3B, C11orf52, SLC4A7, TMEM87A, NPL, EMB, PCNA, DNA2, TMEM86A,
MMP12, CTSD, AXL, RASGRP3, TUBB, FCGR1A, CR1, MX2) previously ascribed to mouse
TAM [45,46,47]. However, in response to ANG-2/TGF-β and PlGF/TGF-β treatments, TEM
down-modulated the expression of genes involved in macrophage differentiation (Fig. 5) and
started to acquire the profile (RGS1, CXCL11, CXCL9, STAT1, IFIH1, ISG20, NT5C3, ADC,
PDGFRL, TNF-ASF12, IFIT5, RGS10, TRAF3IP3, CIDEB, APOBEC3A, PYGL, RRM1, MAF,
NLRC4, IL10, MYC, DUT, POLE4, CXCL17) of dendritic cells matured in vitro by exposure to
lipopolysaccharide and interferon-gamma [48,49]. Along these lines, genes encoding for dendrit-
ic cell markers, antigen processing and adaptive immune response were upregulated while genes
involved in immune suppression showmarkedly decreased expression (Fig. 5 and [38]). Finally
the expression of genes related to adhesion and migration were up- and down-regulated respec-
tively indicating that TEMmobility was strongly reduced; an observation consistent with the ar-
rest of their cell cycle and the alteration of their differentiation program (Fig. 5 and S5 Table).
Along these lines, we observed experimentally that ivdTEM treated with PlGF/TGF-β/TIE-2i
display reduced mobility towards the human epithelial tumor cell line MDA-231 (S3A Fig.) and
slowed down the growth of MDA-231 cells (S3B Fig.)
Taken together, our results suggest that ANG-2/TGF-β and PlGF/TGF-β treatments are not
only anti-angiogenic but also shift the gene expression profile of monocytes toward the one of
cells promoting immune surveillance, thereby limiting tumor growth.
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Validation of the predictions in patient TEM- TGF-β/TIE-2 pathways may
represent a therapeutic target to inhibit tumor TEM proangiogenic
function
We next sought to validate the computationally predicted treatments in TEM isolated from pa-
tient breast carcinoma. Tumor TEM were exposed to TIE-2 kinase inhibitor combined with
TGF-β and simultaneously engaged their VEGFR-1 using VEGF (alternatively PlGF, Table 4
and Fig. 4). This combined treatment strongly reduced the pro-angiogenic activity of tumor
TEM in the mouse cornea vascularization assay (Fig. 6A and B) and decreased the expression
Fig 5. Gene expression changes in monocytes treated with TGF-β/ANG-2 and TGF-β/PlGF relative to untreated and VEGF/TNF-α cells. 398
significantly (P 0.05) differentially expressed genes were manually annotated and classified in categories (S5 Table). In each category the percentage of
up- and down-regulated genes are displayed as well as the total number of genes (under brackets). 50 genes could not be assigned to these categories.
doi:10.1371/journal.pcbi.1004050.g005
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of TIE-2 and VEGFR-1 (Fig. 6D). Furthermore, this treatment reduced the secretion of IL-6,
IL-8, MMP9, bFGF and VEGF, consistent with a paracrine profile shifted toward a M1-like
phenotype and closer to the one of blood TEM (Fig. 6C and 1B). Conversely, TEM from patient
blood exposed to the combined treatment of TNF-α/PlGF/ANG-2 increased their pro-angio-
genic activity in the mouse cornea vascularization assay (Fig. 6B) and was associated with sig-
nificantly higher secretion of IL-1β, IL-6, IL-10, MMP9 and VEGF (Fig. 6C) and increased
expression of TIE-2 and VEGFR1 (Fig. 6D). These results highlighted the validity of our com-
bined experimental and computational approach to revert the pro-angiogenic phenotype of
TEM and revealed, for the first time, that tumor TEM remain plastic cells representing attrac-
tive targets for anti-angiogenic therapies.
Fig 6. Controlling the pro-angiogenic activity of TEM from breast cancer patients. (A and B) In vivo corneal vascularization assay, as described in
Fig. 1A, showing the variations in the pro-angiogenic activity of patient TEM in response to in silico predicted treatments. TIE-2 kinase inhibitor/TGF-β/VEGF
treatment decreased tumor TEM pro-angiogenic activity while TNF-α/PlGF/ANG-2 treatment increased the pro-angiogenic activity of blood TEM. Bars are
500 and 250 μm in A and B respectively. Cornea and iris are depicted by double-head and single arrows respectively. Bar graph represents a quantification
of the vascular network of the cornea and the iris. (C) Variations of patient blood and tumor TEM secretion profiles in response to TNF-α/PLGF/ANG-2 and
TIE-2 kinase inhibitor/TGF-β/VEGF treatments. Angiogenic factors are boxed. No significant variations were detected for IL-4 and TNF-α. (D) Variations of
patient blood and tumor TEM expression of TIE-2 and VEGFR-1 in response to the same treatments. Fold increase to isotype control antibody is indicated,
similarly as in Table 2. Shown are cumulated data (C, D) or representative results (A and B) of 3 to 5 experiments. Significant variations (* P< 0.05, T test).
doi:10.1371/journal.pcbi.1004050.g006
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ANG-2 and PIGF survival analysis on breast cancer patients
We addressed the question whether or not the expression levels of ANG-2 and PIGF when con-
sidering the overall breast tumor have impact on the survival (considered here as relapse free
survival).
To this end we analyzed a dataset including tumor expression profiles and clinical data of
1809 breast cancer patients [50] and compared two subsets of patients: those with lowest and
highest expression values for ANG-2, PIGF and CD14 (as TEMmarker), using as threshold the
first and fourth quartile respectively. These quartiles were computed independently for each
gene, and the two groups of selected patients resulted from the intersection of them all
(Fig. 7B-F). The Kaplan-Meier plot showed a clear separation between patients with low
(n = 40) and high (n = 62) expression for these three genes, with a p-value of 0.0257 derived
from log-rank analysis (Fig. 7B and F). Interestingly, we observed that the same analysis repeat-
ed for patients with high and low levels of ANG-2 and CD14 or PIGF and CD14 (and not for
the remaining gene) resulted on p-values not statistically significant (0.0587 and 0.521 respec-
tively, Fig. 7C-E), suggesting that the synergistic effect of the corresponding pathways is re-
quired to have a significant impact on the survival.
These results suggest that TEM infiltrating a tumor microenvironment enriched in Ang-2
and PlGF, which synergistically trigger TEM angiogenic activity through Tie-2 and VEGFR-1
(Fig. 4 and 5), may contribute to a worse patient survival. Further, tumor size correlated posi-
tively with the amounts of PlGF and Ang-2 content in the tumor microenvironment (Fig. 7A,
P<0.01) while no significant correlation was observed with VEGF, Ang-1, MCP-1, SDF-1,
TGF-α and TNF-β. Moreover, we measured by reverse phase protein arrays that in tumors the
extent of TEM infiltration was significantly and linearly correlated with PLGF content
(Fig. 7A) thus highlighting that Tie-2 and VEGFR-1 axes, as well as their cognate angiogenic
TEM ligands Ang-2 and PlGF represent attractive therapeutic targets in breast cancer.
Discussion
The key relevance of this study is a comprehensive understanding of the behavior of TEM in
breast tumor vascularization. This goal was achieved by constructing an integrative and predic-
tive model of TEM behavior based on experimental data. This model was interrogated to iden-
tify combined treatments that would alter TEM pro-angiogenic activity. Quite remarkably,
four of the five predicted combined treatments that we validated experimentally proved to be
extremely efficient at inhibiting or promoting tumor TEM proangiogenic activity, demonstrat-
ing the robustness of our model. Furthermore, this study demonstrates that the synergistic ef-
fect of these treatments relies on crosstalk between TNF-R1, VEGFR-1, TGF-β and TIE-2
pathways resulting in altered angiogenic activity (Figs. 2, 4 and 5), modulated expression of an-
giogenic receptors (Fig. 4A) and shifted paracrine profile (Fig. 6C).
Taken together, our results highlight crosstalks between TIE-2, VEGFR-1, TGF-β and TNF-α
pathways of outstanding importance to promote (TNF-α/ANG-2/PlGF) or abrogate (TGF-β/TIE-2
inhibitor/VGFR1 or TIE-2 ligand) patient TEM pro-angiogenic activity.
Another contribution of this study is an effective approach to model relatively sparse data
from distinct individuals (newborns and patients), who are inherently heterogeneous in nature.
This challenge was overcome by a sustained and tight collaboration between the experts in the
fields of computational and experimental sciences throughout all steps of the workflow
(Fig. 1C). By setting up a rigorous experimental design we identified coherent variations and
links across biological replicates and data sets, which provided a robust basis to reconstruct the
TEM signaling network (Fig. 3). Furthermore, the modeling framework was an integral part of
our experimental strategy, enabling the model predictions to address the biological questions,
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an issue that is of particular importance in systems biology [1,51,52]. In a traditional approach,
it would have been unfeasible to experimentally test the complete set of up to three simulta-
neous perturbations using 12 distinct ligands, which would have led to 596 ligand combina-
tions. The physiologically relevant combinations of ligands were discovered by applying the
recently proposed MIS algorithm [43,44] to predict all minimal perturbations in the inferred
regulatory network that can transition TEM into desired steady states (Table 4). The in silico
minimal perturbations predicted by applying the MIS algorithm on the inferred ivdTEM
Fig 7. Tie-2 and VEGFR-1, and Ang-2 and PIGF represent attractive targets in breast cancer (A) Correlation of Ang-2 and PlGF and CD14 protein
expression levels in the tumor with tumor size in 17 patients. The significance of their linear correlation is shown by Pearson r and p values. (B-F)
Survival analysis. The good prognostic effect of the lower expression of CD14, ANG-2 and PIGF (B) is reflected by the clear separation from the over
expression group on the Kaplan-Meier plot, with a P value of 0.0257 from a Log-rank test (F), whereas only ANG-2 (C) or PIGF (D) combined with CD14
separate worse lower and over expression groups, suggesting a synergistic effect of ANG-2 and PIGF to promote CD14-mediated angiogenesis and the
corresponding impact on patient relapse free survival. (E) Shows the survival curve of lower expression patients for the three cases.
doi:10.1371/journal.pcbi.1004050.g007
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regulatory network comprised not only a handful of the set of perturbations (or ligand combi-
nations) and they were all shown to be experimentally valid when tested on ivdTEM and pa-
tient TEM (Figs. 4 and 5). The in silico prediction algorithm helped us to focus on the most
clinically relevant monocytic ligands and to unravel treatments abrogating TEM pro-angiogen-
ic activity at breast tumor sites. These results highlight the importance of mutual relationship
between experimental and computational sciences. Furthermore, the combined computational
and experimental approach followed in this study may provide a general strategy to study the
behavior of limited cell subsets from patients in cancer and other diseases.
The main outcome of this modeling strategy for experimental and clinical oncology is the
validation of treatments abrogating tumor TEM pro-angiogenic activity and thus simulta-
neously revealing their functional plasticity. Our study shows that treatments targeting TEM
plasticity may constitute a valid therapeutic strategy to shift TEM to acquire a more anti-tumor
M1-like phenotype. Moreover, the relapse free survival analysis showed a clear separation be-
tween patients with low and high expression for pro-angiogenic genes (ANG-2 and PIGF), and
suggested that the synergistic effect of the corresponding pathways is required to have a signifi-
cant impact on the survival.
Overall, our results obtained by employing the combined modeling and experimental ap-
proach suggest novel treatments for abrogating tumor TEM pro-angiogenic activity and reveals
the functional plasticity of TEM.
Materials and Methods
A detailed procedure of the methods used is provided as supplementary information in
S1 Text.
Ethics statement
This study was approved by the ethics committee of the University Hospital of Lausanne (refer-
ence number 170/07). Patient or subject tissue specimens were obtained according to the decla-
ration of Helsinki and upon written informed consent.
Patient and tissue specimens
A series of 40 primary invasive breast carcinoma specimens (Table 1) were resected from pa-
tients with breast cancer and tumors enzymatically dissociated as described [53]. All patients
underwent surgery and sentinel node biopsy before treatment. The presence of nodal metasta-
ses and tumor pathological features were confirmed histologically and are detailed in Table 1.
All patients were untreated before surgery. Peripheral blood was collected before surgery and
processed as described [54].
TEM differentiation and treatment
CD34+ hematopoietic progenitors from cord blood were isolated by immunomagnetic selec-
tion (StemCell Technologies Inc.) and cultured as previously described [40]. At day 6, cells
were activated for 2h at 37°C with 100 ng/ ml of recombinant ligands (TNF-α 20 ng/ ml),
washed and cultured for 36h in RPMI containing 10% FCS. When two treatments were succes-
sively applied, TEM were first exposed for 2h to a combined treatment of PlGF/TNF-α/ANG-
2, washed and kept in culture for 30h in RPMI containing 10% FCS. They were then exposed
to inhibitory treatments for 2h, washed and kept 24 hours longer in culture. TEM phenotype,
cytokine secretion and pro-angiogenic activity were assessed by flow cytometry and in vivo or
in vitro vascularization assay, respectively. Alternatively TEM were isolated from patient
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peripheral blood or tumor by CD14 immunomagnetic selection, exposed to treatments for 36h
(30h exposure to angiogenic and inflammatory factors followed by 6h exposure to TIE-2 kinase
inhibitor at 8 μM) and extensively washed. TEM viability was not affected under the different
conditions of stimulation used and was> 95%
Experimental design
We undertook a rigorous experimental design consisting in profiling changes in phenotype, cy-
tokine secretion, gene expression and angiogenic activity from the same cell sample in response
to treatments. Changes induced by the treatments were normalized to untreated cell in each bi-
ological replicate and cumulated across the treatments. In this study, a biological replicate was
a population of ivdTEM from a distinct cord blood and exposed to the same treatment. Hence,
biological replicates originated from distinct individuals (newborn or patients). This experi-
mental design was kept rigorously for each biological replicate to allow analysis across biologi-
cal replicates and data sets.
Analysis of cell phenotype and cytokine secretion by flow cytometry
Following blocking of Fc receptors with antibodies, cells were labeled with CD14 (PerCP-
Cy5.5), CD11b (FITC), TIE-2 (Alexa 647), VEGFR-1 (PE), TGFBR-1 (Pacific Blue), TNF-R1
(Pacific Orange), CXCR4-, CCR5-, α5β1-biotinylated specific antibodies (followed by strepta-
vidin-Marina Blue) and analysed by flow cytometry using a Facs LSRII (BD Biosciences)
equipped with a 610/20 nm filter on the violet detector. Pacific Blue and Pacific Orange NHSE
(Invitrogen) were used to couple TGFBR-1 and TNF-R1-specific antibodies respectively as well
as the corresponding isotype controls. The cell populations were manually examined based on
their CD14 and CD11b intensities to identify DN, SP and DP cell populations and the frequen-
cy count and a mean intensity value for each channel were calculated. Secreted cytokines and
angiogenic factors were quantified in cell conditioned medium using FlowCytomix technology
(Bender MedSystems and RnD). Importantly, VEGF and PlGF were used as treatments (see in
vitro TEM differentiation and treatments above) and also measured in conditioned medium as
angiogenic factors secreted by TEM in response to the treatments (this section).
In vivo and in vitro angiogenesis assay
Mouse experiments were approved by the veterinary service of Vaud Canton. The bacterial li-
popolysaccharide membrane receptor CD14 is a component of the innate immune system
mainly expressed by monocytes and macrophages and commonly used as a marker of these
cell populations. Monocytes were isolated by CD14 immunomagnetic selection from patient
tissue. For in vivo corneal vascularization assay, 20,000 CD14+ cells isolated by positive immu-
nomagnetic selection (Stemcell Technologies) from peripheral blood (purity>95%) or dissoci-
ated tumors (purity>85% with no detectable CD45- contamination) were injected (5μl) into
the stromal part of the corneas of anesthesized NOD-scid IL2Rγnull mice [39] using a 35 gauge
nanofil injection kit (WPI, Stevenage, UK). Cornea vascularization was monitored with a digi-
tal stereomicroscope (Leica). Mice were euthanized 25 days post-injection and isolated eyes
were fixed in 4% PFA, cryoprotected in a 30% sucrose solution and embedded in Yazulla
media (30% egg albumin, 3% gelatin). Vascularization was assessed by immunostaining of the
sagittal sections (10μm) with CD31-specific antibodies (Platelet Endothelial Cell Adhesion
Molecule-1, PECAM-1) using a Zeiss motorized Axio Imager M1 fluorescent microscope. Reti-
na was used as a positive control in all CD31 stainings. Quantification was performed with
Image J software by measuring the fraction of the iris and cornea surface area containing ves-
sels (CD31 positive surface areas of the iris and cornea/ surface area of the iris and cornea).
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This ratio was set up at 1 for the control eyes (no cell injected) and the data were normalized to
the control (AU). In vitro angiogenesis sprouting assay was performed with HUVEC spheroids
as previously described [40]. The corneal angiogenesis assay is still considered one of the best
in vivo assays [55]. However, the surgical procedure is technically difficult and the assay time
consuming. Therefore, we use in vitro angiogenesis sprouting assay [56] to assess the impact of
multiple treatments and we validated the most relevant one in vivo.
Reagents and antibodies
Chemicals unless indicated otherwise were from Sigma-Aldrich. Common stocks of cytokines,
inhibitors and assay reagents were used to minimize experimental variability. Human recombi-
nant cytokines were purchased from PeproTech (London, UK) and R&D Systems. All the anti-
bodies used are listed in S1 Table. TIE-2 kinase inhibitor compound 7 was from Alexis
Biochemicals (San Diego, CA).
Statistical analysis and data treatments
Statistical analysis was performed using GraphPad Prism version 4.00 for Windows, GraphPad
Software, San Diego, California, USA. Unless indicated differently, T test was used to deter-
mine p values. A p value< 0.05 was considered statistically significant. All data shown are
means ± standard deviation. The effect of each treatment on the phenotype and secretions of
TEM was calculated as the log2 of the mean fluorescence intensity (MFI) percent change com-
pared to untreated cells and a heatmap produced with R (http://www.R-project.org).
Estimation of the relative contribution of each cell population in the total
cytokine production
Cumulated secretions from DN, SP and DP (i.e. ivdTEM) were measured experimentally and
the secretions of each population mathematically inferred. For a given treatment, let Na, Nb
and Nc be the relative number of cells present in each population (a = DN, b = SP, c = DP) and
K be the amount of cytokine experimentally measured and expressed as a percentage of change
of cytokine secretion to untreated cells. Then the relative contribution C of each population
was expressed as:
CaNaþ CbNbþ CcNc ¼ K
Using three independent biological replicates (1, 2, 3) and their associated cytokine measure-
ments (K1, K2, K3) we could write the following three equations:
CaNa1þ CbNb1þ CcNc1 ¼ K1
CaNa2þ CbNb2þ CcNc2 ¼ K2
CaNa3þ CbNb3þ CcNc3 ¼ K3
The unknowns were Ca, Cb, and Cc while Na, Nb and Nb have been obtained from cytoﬂuori-
metry data. These equations were solved for all possible combinations of 3 biological replicates
(4 to 84) and the median of the obtained C coefﬁcients calculated. The coefﬁcients were then
used to infer the amount of cytokine by DN, SP and DP cell populations. In the few instances,
the inferred cytokine amount was lower than 0% of untreated cells and the predicted value was
set to a minimal positive value (1%).
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Identification of the links between treatment, receptor and cytokine
Within the TEM regulatory network, a link represents an effect (increase or decrease) on either
receptor expression or cytokine secretion in response to single or combined ligands (Fig. 3). Of
note, some treatments and secreted cytokines are identical. We applied the three following cri-
teria to identify a link between treatment/receptor/cytokine. We retained only the links that are
reproducible, of sufficient amplitude and coherent. Only 8% of the possible links matched
these three criteria and were retained to construct the TEM regulatory network. A link was
considered as reproducible when the treatment induced a reproducible effect across at least 3/4
of the biological replicates. Second, a treatment was retained if it induced a change of sufficient
amplitude, i.e. when the effect of the treatment on receptor and cytokine was among the upper
(the treatment increases the expression of a receptor or a cytokine) or lower (the treatment de-
creases the expression of a cytokine or a receptor) quartile of variation. Third, only coherent
links were retained meaning that they should be always correlated or anti-correlated across the
treatments, and not sometimes correlated and other times anti-correlated. As an example, a re-
ceptor A and a cytokine B are linked when they show similar or/and opposite variations across
the treatments e.g. receptor A up-regulated)/ cytokine B up, and/or receptor A down/cytokine
B down. The list of the retained links is provided in S4 Table.
Computing minimal all perturbations sets in ivdTEM regulatory network
The interactions between treatment/receptor/cytokine as predicted by our experimental and
computational approach (see previous section) were used to generate the dynamical regulatory
network of ivdTEM (Boolean equations are provided in S6 Table). The MIS algorithm pro-
posed in [43,44] was then applied to compute all possible minimal perturbation sets to force
the network into desired steady state or phenotype. The MIS algorithm starts by unrolling the
inferred regulatory network of ivdTEM into a tree-like structure starting from the nodes which
have a fixed polarity (i.e. either high or low) in the desired final steady state. In the angiogenesis
model of ivdTEM, the nodes corresponding to TIE-2 and VEGFR-1 are assigned a fixed polari-
ty of either both high or both low for highly pro-angiogenic and weakly pro-angiogenic steady
states respectively. The nodes with the fixed polarity are referred to as the root nodes of the net-
work. The network is unrolled along a path in the regulatory network until a duplicate node is
found. At that instance the unrolling process is terminated along this path. Once the network is
unrolled along all paths originating from the root node, the MIS patterns are generated by
scanning this unrolled network in two iterations. In the first iteration, the required polarity (i.e.
over-expression or knock-down) of each node is propagated from the root node to the leaf
nodes. In the second iteration, possible perturbations that can lead to the required polarity at
each node are listed by scanning the unrolled network in the reverse order from the leaf nodes
towards the root node in the breadth first manner. When two paths merge at one node, then
only those MIS vectors that are compatible (i.e. the same node is not over-expressed on one
path and knocked-down on the other path) along both the paths are taken into consideration
while scanning the rest of the network. This process when terminates at the root node, only
MIS vectors that have been compatible throughout the unrolled network shall remain in the
list. The MIS algorithm does not involve explicit enumeration of perturbation patterns but
rather generates these patterns by traversing the topology of the network ensuring that only the
patterns leading to a desired cellular behavior are generated. Detailed methodology for genera-
tion of the MIS vectors and the network unrolling process are further described in [43,44].
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Gene expression profiling
Total RNAs from 100 000 monocytes were isolated and purified with the Qiagen RNeasy
micro plus kit. RNA samples were hybridized to Affymetrix Human Gene 1.0 ST Arrays and
images were processed to obtain probe intensities using standard procedures at the GTF (Gene
Technology Facility, CIG, University of Lausanne). Background subtraction, RNA normaliza-
tion and probeset summarization were performed using the Affymetrix Power Tools software
package (Affymetrix CEL files). Sample correlation was performed on the top 1000 expressed
probesets using Bioconductor affy and affyPLM packages in R [57]. This analysis indicated sep-
arate clustering of VEGF/TNF-α and ANG-2 or PIGF/TGF-β samples. Differentially expressed
genes between different treatments were detected by fitting linear models and computing em-
pirical Bayes moderated t statistics, comparing two groups at a time, using the limma package
in R [58]. P values were adjusted for multiple comparisons using the Benjamini Hochberg pro-
cedure [59] and genes with an adjusted p value of< = 0.05 were selected as differentially ex-
pressed. For pathway analysis, differentially expressed genes were ranked according to fold
change (high to low) comparing two treatments and Gene Set Enrichment Analysis (GSEA)
was performed on the ranked lists against MSigDB gene sets using the NCBI gene id as a
unique identifier [60]. Enrichment p values were adjusted for multiple comparisons using the
Benjamini Hochberg procedure [59]. The microarray data from this publication have been sub-
mitted to the GEO database http://www.ncbi.nlm.nih.gov/geo/info/linking.html and assigned
the identifier GSE34559.
Survival analysis
Publicly available normalized expression data from 1809 breast cancer patients was down-
loaded from http://kmplot.com [50]. For the relapse free survival analysis we selected lowest
and highest expression values of 205572_at, 209652_s_at and 201743_at probes, corresponding
with ANG-2, PIGF and CD14 genes respectively, using as threshold the first and third quartile
respectively. These quartiles were computed independently for each gene, and the two groups
of selected patients resulted from the intersection of them all (see Fig. 7). To generate the
Kaplan-Meier plots and to evaluate the separation between groups (log-rank statistic) we used
the survival package in R. Tables with the resulting data and R scripts are included in supple-
mentary table 7.
Supporting Information
S1 Text. Tumor tissue processing, TEM differentiation in vitro, TEM stimulation, in vitro
angiogenesis assay, migration assay, tumor growth inhibition assay and protein profiling
in tumor tissues.
(DOCX)
S1 Fig. TEM co-express Tie-2 and VEGFR-1. (A) Gating strategy of monocytes in patient pe-
ripheral blood and dissociated breast tumor. CD11b+, CD14+ cells are gated from live and sin-
gle cell population and the expression of Tie-2 and VEGFR-1 was assessed in this population
either in peripheral blood (A) or dissociated tumors (B). Isotype control antibodies were used
to assess the expression of Tie-2 and VEGFR-1 in peripheral blood (A) and dissociated tumors
(B). (C) In breast tumor tissue more than 95% of TEM co-express Tie-2 and VEGFR-1 as
shown by confocal microscopy images of sections of frozen breast carcinomas and Facs analy-
ses (B).
(TIFF)
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S2 Fig. In vitro differentiated TEM: characterization at resting state and upon stimulation.
Patient TEM are (CD11b-, CD14+ i.e. double positive DP cells) while in vitro differentiated
cells encompassed three cell populations: DN: double negative (CD11b-, CD14-), SP: single
positive (CD11b-, CD14+) and DP: double positive (CD11b+, CD14+). The frequency of these
population are as follows: DN (53.7%±10.8), SP (30.4%±11.9), DP (16.1%±5.6). In vitro differ-
entiated TEM correspond to the DP cell population and display a phenotype and functions
intermediate to blood and tumor patient TEM (Fig. 1A and B and Tables 2 and 3). (A) The ex-
pression of receptors at the surface of TEM differentiated in vitro was measured by flow cytom-
etry at resting state in DN, SP, and DP (i.e. TEM) cell populations. Shown are cumulated data
of 10 independent experiments. Box plots represent values between 25th and 75th percentile
with a line at the median (50th percentile). The whiskers extend above and below the box to
show the highest and the lowest values. Significant variations between SP and DP cell pheno-
types are indicated with asterisks in the DP box plots ( P< 0.05,  P< 0.01, T Test). (B)
In vitro differentiated cells were exposed to different combinations of ligands and changes in
receptor expression at the surface of DN, SP and DP (i.e. TEM) cell populations were measured
by flow cytometry 36 hours post-treatment and displayed as mean log2 ratios relative to un-
treated cells. Shown are cumulated data of 3 to 9 independent experiments. Significant varia-
tions (P< 0.05, T test) in VEGFR-1 and TIE-2 expression in SP and DP cell populations are
indicated with an asterisk in the heatmap. The corresponding experimental data and all P val-
ues are available in S2 Table. (C) Secretion of cytokines and angiogenic factors in response to
treatments in DN, SP and DP (i.e. TEM) cell populations differentiated in vitro. In contrast to
receptor expression, TEM secretions were released in the culture medium and could not be
measured in individual cell populations. Thus, cumulated TEM secretions from DN, SP and
DP cell populations were measured experimentally and the secretions for each individual
population were mathematically inferred (see Materials and Methods) and displayed as mean
log2 ratios relative to untreated cells. Angiogenic factors are boxed. Shown are cumulated data
of 5 to 10 independent experiments. The corresponding experimental data are available in
S2 Table.
(TIFF)
S3 Fig. Impact of PlGF/TGF-β/TIE-2inhibitor treatment on ivdTEM functions. ivdTEM
were left untreated or treated with PlGF/TGF-β/TIE-2inhibitor and (A) their aptitude to mi-
grate towards MDA-231 breast epithelial cells assessed in vitro (n = 3), (B) their ability to slow
the growth of MDA-231-GFP cells was measured in a 48h co-culture assay (n = 3). (C) In vitro
angiogenic assay: representative images of HUVEC cell sprouting in the presence or absence of
ivdTEM.
(TIFF)
S1 Table. Antibodies used for the study listed by application.
(DOCX)
S2 Table. Expression of receptors at the surface of TEM differentiated in vitro in response
to treatments. Changes are expressed relative to untreated cells (untreated cells: 100%). Signifi-
cance of these changes are indicated in a P value table (T test) for SP and DP cell populations.
(XLS)
S3 Table. Changes in cytokine secretion experimentally measured in the conditioned medi-
um of TEM differentiated in vitro in response to treatments (untreated cells: 100%).
(XLS)
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S4 Table. Links between treatment, receptor and cytokine in DP cell population i.e. TEM.
All the links retained for the construction of TEM dynamical regulatory network are shown.
(XLS)
S5 Table. List of genes from in vitro differentiated TEM displaying significant variations of
their expression in response to ANG-2/TGF and PlGF/TGF treatments. Genes specifically
regulated by each of these treatments were classified in PlGF/TGF and ANG-2/TGF unique
lists. Genes affected by both treatments were listed in ANG-2/TGF PLGF/TGF intersect.
(XLSX)
S6 Table. Boolean equations used for representing TEM regulatory network shown in
Fig. 3.
(TXT)
S7 Table. R scripts and normalized expression and clinical data from 1809 breast cancer
patients to perform the survival analysis and generate Kaplan-Meier plots.
(XLS)
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